Lineage Cell Therapeutics (LCTX) Operating Income Growth (5y) (2015 - 2026)
Lineage Cell Therapeutics (LCTX) Operating Income Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - |
| 4 | BeOne Medicines | 469.79 Bn | 465.00 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.62 Bn | 62.62 Bn | - |
| 8 | Argenx Se | 56.18 Bn | 50.99 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Lineage Cell Therapeutics | 248.70 Mn | 185.99 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.50% |
| Dec 31, 2025 | -2.17% |
| Sep 30, 2025 | 10.85% |
| Jun 30, 2025 | -25.31% |
| Mar 31, 2025 | 2.65% |
| Dec 31, 2024 | 5.75% |
| Sep 30, 2024 | 14.54% |
| Jun 30, 2024 | 11.52% |
| Mar 31, 2024 | 12.19% |
| Dec 31, 2023 | 8.84% |
| Sep 30, 2023 | 8.33% |
| Jun 30, 2023 | 11.29% |
| Mar 31, 2023 | 11.43% |
| Dec 31, 2022 | 7.04% |
| Sep 30, 2022 | 11.21% |
| Jun 30, 2022 | 13.14% |
| Mar 31, 2022 | 10.70% |
| Dec 31, 2021 | -20.20% |
| Sep 30, 2021 | 6.46% |
| Jun 30, 2021 | 13.24% |